Somnomed Ltd. Executive Update and FY26 Results
Key points
- Amrita Blickstead steps down as Co-CEO
- Karen Borg assumes role of CEO
- FY26 unaudited revenue: $114M-$115M
- Targeting high single-digit revenue growth in FY27
- Launch of VirtusTM for OSA and sleep bruxism
Full summary
Somnomed Ltd. announced that Ms. Amrita Blickstead has stepped down as Co-CEO, with Ms. Karen Borg taking over as CEO. The company reported unaudited FY26 revenue of between $114 million and $115 million, below the latest guidance of $119 million to $126 million, due to market dynamics in Europe and the appreciation of the Australian dollar. The company achieved double-digit growth in EBITDA by maintaining a disciplined approach to cost and capital management. Somnomed also launched VirtusTM, a therapy for patients with OSA and coexisting sleep bruxism. The company targets high single-digit revenue growth in FY27, with guidance to be issued alongside the FY26 year-end results.
Guidance
FY26 revenue: $114M-$115M, FY27 revenue growth: high single-digit
Outlook
Somnomed targets high single-digit revenue growth in FY27, with FY27 guidance to be issued on or around 28 August 2026.
Summary generated by a large language model. Please interpret with care.